Hepatitis B Surface Antigen, ad, Recombinant (HBsAg)

Catalog No : USB-H1909-01Z
581.63€
0.00€

Shipping cost plus VAT not included , delivery in 7-14 business days

Product name Hepatitis B Surface Antigen, ad, Recombinant (HBsAg)
Catalog No USB-H1909-01Z
Supplier’s Catalog No H1909-01Z
Supplier US Biologicals
Source antigen Saccharomyces cerevisiae
Reactivity
Cross reactivity
Applications
Molecular weight 24
Storage 4°C
Other names
Grade Highly Purified
Purity ~95% by SDS-PAGE
Form Supplied as a liquid in PBS, pH 7.2. No preservative added.
Reactivity life 6 months
Note For reserch purpose only
Purity ~95% by SDS-PAGE
Description Recombinant HBsAg subtype ad. Does not contain a fusion partner. HBsAg is the surface antigource: S. cerevisae Purity: ~95% by SDS-PAGE Concentration: ~1mg/ml Form: Supplied as a liquid in PBS, pH 7.2. No preservative added.en of the Hepatitis-B-Virus (HBV). The antigenic determinant of the protein moiety of the HBsAg determines specific characteristics of different serotypes and provides the basis of immunodetection. HBsAg has antigenic heterogeneity, specifically, two pairs of sub specific determinants, d/y and w/r allow the following combinations: adw, ayw, adr, ayr. Hepatitis B is an infection of the liver caused by the hepatitis B virus. Approximately 5-10% of adults and 90% of babies who are infected with HBV will go on to carry the virus for the rest of their lives. These people will pass the virus onto others. HBV is excreted in body fluids such as semen, saliva, blood and urine in persons with acute or chronic infection. The route of transmission can include homosexual or heterosexual activity, blood-borne exposure (needles, transfusion), mother-infant, close personal contact and even by consuming contaminated food or water. Thus, Hepatitis B has become a major public health concern. When HBV invades the body it causes liver damage through induction of auto-immunity. Liver cell injury results from cytotoxic T cell activity rather than viral cytotoxic activity. The principal screening test for detecting current (acute or chronic) HBV infection is the identification of HBsAg, an envelope lipoprotein. This is the first immunological marker to appear in a patient’s serum and exist in high quantities in the blood. Patients who are HBsAg positive develop chronic persistent hepatitis (CPH) and chronic active hepatitis (CAH). Patients with CPH usually remain in good health. Those with CAH have progressive liver damage with the outcome being portal fibrosis, cirrhosis, or hepatocellular carcinoma. Screening for HBsAg is recommended for all donors, pregnant women and those individuals who at high risk. Presence of this marker is conclusive proof of HBV infection. The immunoassay measures HBsAg through antigen-antibody interactions. Applications: Suitable for use in ELISA and Western Blot. Other applications not tested. Recommended Dilutions: Optimal dilutions to be determined by the researcher. Storage and Stability: May be stored at 4°C. For long-term storage, aliquot and store at 4°C. Do not freeze. Aliquots are stable for 6 months after receipt. For maximum recovery of product, centrifuge the original vial prior to removing the cap. Further dilutions can be made in assay buffer.